Navigation Links
VaxGen Restructures Following Termination of Proposed Merger
Date:4/9/2008

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, announced that the Company has initiated a restructuring to minimize expenses following the termination of the proposed merger between VaxGen and Raven biotechnologies, inc. VaxGen has moved to terminate the staff which it had retained in anticipation of the needs of the merged company. As a result, VaxGen will be terminating approximately 75% of its remaining staff of 22 persons, including Matthew Pfeffer, the Company's CFO and Senior Vice President of Finance and Administration.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

"It is quite unfortunate that VaxGen must now terminate so many of our most capable and loyal staff, including Matt Pfeffer," said James P. Panek, VaxGen President and CEO. "Matt's performance since joining VaxGen in 2006 has been nothing short of outstanding. His talents, both as CFO and as a senior leader, became increasingly obvious as he brought VaxGen current with its financial filing obligations, worked to reduce expenditures and financial liabilities, and contributed notably to our pursuit of strategic initiatives."

"My tenure at VaxGen, while filled with many challenges, has also been marked by many successes and opportunities to work with many remarkable colleagues," said Matthew Pfeffer. "With VaxGen's financial filing obligations now current and the scope of its business greatly reduced, I am confident that VaxGen can ably fulfill all required financial and administrative responsibilities in my absence."

VaxGen's near term plan of action is quite straightforward: reduce staffing and expenses to reflect the realities of not merging with Raven; continue our efforts to sell the Anthrax vaccine program and manufacturing facility, and deal as best we can with our lease obligations; and importantly, reconfigure our board to deal with the future course of the Company. VaxGen is speaking with a number of its largest stockholders in order to get their input, including suggestions for potential new board members, and will be completing this reconfiguration process as expeditiously as possible.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding restructuring of VaxGen, the reconfiguration of its Board of Directors and its continuing efforts to divest assets. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven
2. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
3. Pharmos Restructures Operations in Israel
4. The Quantum Group Announces Increased Patient Enrollment Following Medicare Advantage Open Enrollment Period
5. New York City Staffing Company Charged With Violating H-1B Program Following U.S. Labor Department Finding Almost $3 Million in Back Wages Due 156 Workers
6. Following School Suicide, National Childrens Charity Issues Tips and Free Resources to Help Prevent 3rd Leading Cause of Death Among Youth
7. Heart attack rates fall following national smoking bans
8. Reynolds American Subsidiary to Receive Payment Following Gallaher Joint-Venture Termination
9. Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year
10. Surgical site infections more common than expected following breast procedures
11. Uninsured More Likely to Die From Cancer Following Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: